PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Go online to PeerView.com/QDX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases discusses guidance for healthcare professionals involved in the treatment of patients with COVID-19. Upon completion of this activity, participants will be able to: Describe the epidemiology and virology of coronavirus disease 2019 (COVID-19), Evaluate patients with suspected COVID-19 infection in accordance with current guidance from the Centers for Disease Control and Prevention (CDC), recognizing that recommendations may be adapted by state and local health departments to respond to rapidly changing local circumstances, Assess the efficacy, safety, and appropriate clinical utilization of current and emerging COVID-19 management and prevention strategies, Employ evidence-based protocols to provide appropriate care for patients with suspected or confirmed COVID-19.

Go online to PeerView.com/HWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the diagnosis and treatment of spinal muscular atrophy in a new era of therapy. Upon completion of this activity, participants should be better able to: Employ current recommendations for screening and diagnosis of patients suspected to have spinal muscular atrophy (SMA), Recognize clinical signs and symptoms associated with early manifestations of SMA from birth to adulthood, Apply current data on the efficacy, safety, and tolerability of approved disease-modifying therapies for SMA from infancy through adulthood, Counsel patients and/or their parents/caregivers regarding the need for ongoing supportive care to optimize treatment outcomes.

Go online to PeerView.com/GVH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent approval of newer JAK inhibitors and new evidence on emerging JAK-targeting strategies have raised additional questions over optimized treatment selection in myelofibrosis (MF) and awareness of clinical factors that can influence therapeutic selection. Additionally, newer dynamic risk-assessment models have allowed for more precise characterization of this disease at diagnosis and during the treatment course. In the wake of these advances, understanding how to effectively personalize therapeutic management based on the modern diagnostic and risk-assessment tools while ensuring safe usage of JAK inhibitors is crucial to maximizing beneficial patient outcomes in MF. In a recent live webcast, our panel of experts used the latest real-world evidence to confirm the core therapeutic role for JAK inhibitor–based strategies in MF, highlighting modern diagnostic and risk-assessment strategies that have informed an individualized treatment approach. During a unique practicum session, the panel offered practice strategies using real-world case scenarios, walking through selection of JAK inhibitor–based options across the MF disease continuum to improve patient outcomes. Upon completion of this activity, participants should be better able to: Recognize clinical and molecular/mutational features that can be used for diagnosis and risk stratification in myelofibrosis, Review the latest efficacy and safety evidence about approved and emerging JAK inhibitors as well as other targeted therapies in the management of myelofibrosis, Design safe, risk-adapted treatment regimens for patients with symptomatic and asymptomatic myelofibrosis, including those refractory to front-line JAK inhibitor therapy.

Go online to PeerView.com/BKK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, breast cancer experts discuss the latest evidence on the use of CDK4 and 6 inhibitors in the management of patients with HR-positive, HER2-negative breast cancer. An essential overview of mechanisms of action of this therapeutic class, similarities/differences among the agents, and latest approvals/indications is provided, along with a summary and analysis of the current state of the science. Practicalities of clinical integration of the CDK4 and 6 inhibitors are also explored, with a focus on navigating the current treatment landscape and making individualized clinical decisions. Upon completion of this activity, participants should be better able to: Describe the rationale for use, mechanism of action, and characteristics (including similarities/differences) of the CDK4 and 6 inhibitors in breast cancer, Analyze the latest efficacy (including OS), safety, and other key data from clinical trials assessing CDK4 and 6 inhibitors in breast cancer, and relevant implications for clinical practice, Discuss the relevant patient-, disease-, and treatment-related factors as well as promising prognostic/predictive biomarkers that could be used to guide selection of patients who would benefit from CDK4 and 6 inhibitors, Incorporate CDK4 and 6 inhibitors alone or in combination into treatment plans for appropriate patients with hormone receptor–positive, HER2-negative advanced breast cancer according to relevant evidence, clinical guidelines, predictive factors, and patient needs and preferences, Manage treatment-related toxicities in patients with breast cancer undergoing treatment with CDK4 and 6 inhibitors to maintain optimal adherence and promote favorable outcomes.

Go online to PeerView.com/FDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CNE activity, a family nurse practitioner brings the nurse’s perspective to patient care in endometrial and cervical cancer. Kimberly Halla, MSN, FNP-C, discusses modern management techniques for patient’s receiving targeted therapy and immunotherapy, as well as combination therapies, and gives her take on how to approach the unique safety profiles associated with these treatment options. Upon completion of this activity, participants will be able to: Summarize the current treatment and regulatory landscape in the management of gynecologic cancers, including the role of novel targeted, immunotherapeutic, and combination approaches in cervical and endometrial cancers, Describe safety and efficacy evidence surrounding targeted, immune checkpoint inhibitor, and combination strategies for the management of gynecologic cancers, Educate patients about therapeutic and safety considerations associated with recently approved and emerging options for endometrial and cervical cancers, Manage the unique spectrum of adverse events associated with targeted and immunotherapy used to treat endometrial and cervical cancers.

Go online to PeerView.com/KSB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case discussion with fellow Tri Le, MD, and a dialogue with a patient diagnosed with RCC, Robert Wilonsky. Upon completion of this activity, participants will be able to: Evaluate current survival and quality of life evidence in the treatment of advanced renal cell carcinoma (RCC) with targeted therapies, immune checkpoint inhibitors, and combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest evidence, relevant patient- and disease-related characteristics, and patient values and preferences, Recommend effective treatment options for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Implement strategies to mitigate and manage treatment-related complications in patients with RCC.

Go online to PeerView.com/JFB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of available and emerging antiviral therapies for the treatment of influenza. Upon completion of this activity, participants will be able to: Recognize the underutilization of antiviral treatment in the management of influenza despite recommendations from practice guidelines, Summarize the mechanisms of action, efficacy, safety, tolerability, and dosing of currently available and novel/emerging antiviral agents for the treatment of influenza, Incorporate currently available and novel/emerging antiviral therapies into the treatment of patients with influenza according to the latest clinical evidence and guideline recommendations.

Go online to PeerView.com/KNT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an immuno-oncology expert describes the basic biology of how the immune system responds to tumor activity, reviews the pathophysiology of the tumor microenvironment, provides up-to-date data supporting the use of cancer immunotherapies, including immune checkpoint inhibitors, and discusses investigational immuno-oncology pathways, putative targets for novel therapies, and current and emerging prognostic biomarkers to inform clinical treatment decisions. Upon completion of this activity, participants will be able to: Describe the foundational aspects of the immune system’s response to tumor activity through innate and adaptive immunity mechanisms, Review the pathophysiology of the tumor microenvironment and its relationship to tumor evasion and resistance, Characterize the mechanisms of action of the immune checkpoint inhibitors (ie, CTLA-4 and PD-1/PD-L1 inhibitors) and how they differ in their activity and adverse effects from conventional anticancer therapies, Summarize the current FDA-approved indications and investigational approaches with the immune checkpoint inhibitors across different tumors, Discuss investigational immuno-oncology pathways and potential new therapies that may be able to expand on the current therapies or overcome immune evasion and resistance, Assess current and emerging immuno-oncology biomarkers and their potential roles/uses, Integrate the latest immunotherapies and biomarker approaches into cancer care in the context of clinical practice or trials.

Go online to PeerView.com/BBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a leading expert discusses key concepts in oncology and supportive care biosimilars, including how they are defined, the regulatory approval process for these agents, and an overview of data for biosimilars in the treatment and supportive care of cancer patients. Upon completion of this activity, participants will be able to: Describe the biosimilar manufacturing process and differences between biosimilars and originator biologics used in the oncology setting, Discuss the concepts of biosimilar interchangeability, therapeutic equivalence, and safety in the context of the regulatory process, Cite efficacy evidence on the use of biosimilars in the management of solid tumors, including breast cancer, lung cancer, GI cancers, and others, Integrate biosimilars into oncology management plans in order to increase patient access to effective medications and improve health system efficiency.

Go online to PeerView.com/EQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a live symposium recently held in West Palm Beach, Florida, leading experts on multiple sclerosis (MS) dive into the latest data on approved and emerging therapies for relapsing and progressive forms of MS and offer practical strategies to improve patient management, treatment selection, and outcomes. In addition to exploring the treatment armamentarium for MS, the panel considers the prognostic and predictive utility of serum neurofilament light chain as an emerging biomarker, including how it may affect disease-modifying treatment selection and sequencing. Upon completion of this activity, participants should be better able to: Apply current data on approved and emerging disease-modifying therapies for the treatment of relapsing forms of MS, Employ recent data related to available and investigational therapies for the treatment of progressive forms of MS, Assess available data on the potential prognostic and predictive utility of serum neurofilament light chain levels in patients with MS, Develop strategies based on clinical phenotypes, goals, preferences, and potential biomarker findings when selecting disease-modifying therapies for patients with MS.